Structural insights into NMDA receptor pharmacology
Although these drugs can be used to combat obesity (at this stage we understand most obesity usage is off label[2]), over the last fifteen years they have been predominantly used to treat type 2 diabetes
Therefore, recommendations for the selection of medications to improve cardiovascular and kidney outcomes do not differ for older people
En labsence dagoniste, le domaine extracellulaire du rcepteur est ferm et interagit avec le domaine transmembranaire (entre PDB 6LN2)
Overdosing can lead to undesired side effects, while underdosing may reduce efficacy
NICE guideline NG28 recommends regular monitoring of HbA1c levels (typically every 36 months until stable, then 6-monthly) and assessment of treatment response, tolerability, and cardiovascular risk factors for patients taking GLP-1 receptor agonists